UCBJY News and Press, UCB S.A. ADR From 07/27/20

The following slide deck was published by UCB SA in conjunction with their 2020 Q2 earnings Read more ...

- UCB's resilient product portfolio drives continued company growth BRUSSELS , July 27, 2020 /PRNewswire/ -- Revenue increased to € 2.6 billion and net sales to € 2.5 billion, both +12%, +9% CER or +10% at CER and adjusted for divestitures respectively Unde...

ATLANTA and PARSIPPANY, N.J. , July 7, 2020 /PRNewswire/ -- UCB and Ferring Pharmaceuticals Inc. today announced they have entered into a co-promotion agreement to commercialize the prefilled syringe formulation of CIMZIA ® (certolizumab pegol) in the United State...

BRUSSELS , June 12, 2020 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the first presentations of data from the Phase 3 clinical development program of bimekizumab, its investigational IL-17A and IL-17F inhibitor, as part of a virtual session for the Americ...

Underlines UCB's leadership in epilepsy by adding Staccato ® Alprazolam, a drug-device-combination with the potential to be the first on-demand, single-use treatment to rapidly terminate an active epileptic seizure Staccato ® Alprazolam could be a potential solution for 20...

Update on attendance and voting instructions relating to UCB's General Meeting of 30 April 2020 Implementation of Royal Decree n°4 of 9 April 2020 on various provisions regarding the legislation on co-ownership and companies and associations, in the framework of the fight aga...

- The transaction, which was announced October 10, 2019 , will enhance UCB's potential to be a leader in myasthenia gravis by adding zilucoplan , a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside rozanolixizumab , UCB's FcRn target...

Background According to a recent study by Gartner, average duration to finalize a merger or acquisition from the time of public announcement has risen more than 30 percent in the last decade. Gartner analyzed more than 23000 deals among S&P1200 companies since 2010 to come up with th...

UCB SA (UCBJF) Q4 2019 Earnings Conference Call February 20, 2020 08:00 AM ET Company Participants Antje Witte - VP, IR Jean-Christophe Tellier - CEO & Executive Director Emmanuel Caeymaex - EVP & Head, Immunology Patient Value Unit Detlef Thielgen - CFO & EVP Cha...

The following slide deck was published by UCB SA in conjunction with their 2019 Q4 earnings Read more ...